ORIC Pharmaceuticals Presents Positive Enozertinib Data for NSCLC Patients with EGFR Atypical Mutations at ESMO Asia Congress 2025.
ByAinvest
Thursday, Dec 4, 2025 9:45 pm ET1min read
ORIC--
ORIC Pharmaceuticals presented data on enozertinib, a treatment for non-small cell lung cancer (NSCLC) with EGFR atypical mutations, at the ESMO Asia Congress 2025. The trial showed promising results, including an 80% overall response rate and 100% intracranial response rate in first-line patients. Enozertinib also demonstrated a competitive safety profile with manageable on-target toxicity. Enrollment and follow-up continue, with the next update expected mid-2026 ahead of potential Phase 3 trial initiation.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet